Information Provided By:
Fly News Breaks for December 30, 2019
ABEO
Dec 30, 2019 | 07:11 EDT
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Abeona Therapeutics to $11 from $15 to account for the company's recent sale of common stock and pre-funded warrants, telling investors that he believes the funds raised should extend the company's operational runway into mid-2021. The analyst, who believes the company's pivotal EB-101 program for recessive dystrophic epidermolysis bullosa is "likely to be rapid," keeps a Buy rating on Abeona shares.